EN DE
Watch HansBiomed Corporation for free: we tell you when fair value or trend changes.
Data-driven stock valuation

HansBiomed Corporation (042520) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of HansBiomed Corporation stock KRW 13,216, price KRW 14,780, that is 10.6% below the price, quality 31 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7042520007

HC HansBiomed Corporation logo Thin data Nov 10, 2026

HansBiomed Corporation

042520 · KQ
Expensive, weak quality

Our calculation puts a fair price 11% below what the stock costs today.

Low debt
Revenue last quarter +65% vs. a year ago.
Expensive Growth (revenue 5y +2.3 %/yr in KRW)
Mixed vs. peers (4/10)
Fair value 13,216 KRW · Overvalued
Quality 31/100
Loss-making · -15.8% net margin (TTM)
Negative free cash flow
Narrow moat 20/100
Thin data
Estimate
Watch HansBiomed Corporation for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

55,700 KRW 6,370 KRW Fair Value 13,216 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 6,370 KRW – 55,700 KRW · fair‑value band 9,912 KRW – 16,520 KRW · the 14,780 KRW price screens above the 13,216 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 10, 2026.

Follow HansBiomed in your weekly email

Every Wednesday you see whether HansBiomed is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies.

Show moreShow less

The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralized cortical bone stick; SureChip, a cancellous bone chip; OsteoGrow, a demineralized bone matrix inserter; BellaCell HD, an allograft dermal product that transplanted in a patient whose skin has been lost due to breast cancer; and SureDerm, an acellular dermal matrix.

It also offers BELLAGEL, a breast prosthesis, internal, and gel-filled solution; MINT Lift, a PDO thread; EZ-Tcon solution; Lion HT/HN, a hair transplanter body/needle; and Scar Clinic, a scar management solution.

The company was formerly known as Hans Medical Corp. and changed its name to HansBiomed Corporation in June 2000. The company was founded in 1990 and is headquartered in Seoul, South Korea.

Stock analysis

HansBiomed Corporation (042520) currently trades at 14,780 KRW, while our estimate is 13,216 KRW, 11% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 9,912 KRW (bear) to 16,520 KRW (bull), the price of 14,780 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

HansBiomed Corporation reported revenue of 89.8B KRW in FY2025 versus 59.1B KRW in FY2021, a compound +11.0%/yr. Reported net income was −31.3B KRW in FY2025.

Key figures

Market cap 211B KRW (≈ $158M) Micro · P/S ratio 1.95 · EPS (TTM) −1,379 KRW · Net margin −15.8% · Return on equity −29.2% · Return on assets (EBIT) −7.1% (5-year average) · Operating margin 11.3% · Revenue (TTM) 125B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 20 out of 100 (medium confidence).

What moves the price

The share trades about 73% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −11%, 042520 screens richer than that median.

Fair Value

Bear 9,912 KRW Fair Value 13,216 KRW Bull 16,520 KRW
Price 14,780 KRW · Downside -10.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 25
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 23
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 6
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 16/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+10.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.3%
Start year 2020 (pandemic). Over 10 years: +14.4% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−15.6% (2020) → −28.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

042520 screens overvalued: fair value 11% below the price. Compare with Abbott Laboratories, →

Compare HansBiomed Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Fair Value upside −10.6% · Above median
Profitability
Return on assets −24.8% · Bottom 25%
Net margin (12 months) −15.8% · Below median
Operating margin (12 months) 11.3% · Above median
Growth and dividend
Revenue growth (quarter YoY) 65.0% · Top 25%
Balance sheet
Debt / equity 0.18× · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 6.25× · Priciest 25%
P/S (12 months) 1.69× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)19 · sector 17
FUTURE (revenue growth)100 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)91 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs 042520
DexCom, Inc DXCM $79.92 $89.18 +12% vs 042520
Stryker Corporation SYK $324.29 $358.30 +10% vs 042520
STERIS plc STE $257.12 $279.53 +9% vs 042520
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs 042520
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs 042520
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs 042520
Abbott Laboratories, ABT $110.46 $75.28 −32% vs 042520
Medtronic plc MDT $101.59 $65.61 −35% vs 042520
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs 042520

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

HansBiomed Corporation: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "HansBiomed Corporation Fair Value". https://www.fairvalue-calculator.com/stock/042520

Frequently asked questions

Is HansBiomed Corporation (042520) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 13,216 KRW versus a price of 14,780 KRW, about 11% lower (overvalued).
What is the fair value of 042520?
Our estimate for HansBiomed Corporation is 13,216 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 14,780 KRW.
What is the quality score of 042520?
HansBiomed Corporation has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HansBiomed Corporation (042520)?
Our calculated price target is the estimate of 13,216 KRW (as of Nov 10, 2026). Cautious scenario 9,912 KRW, optimistic scenario 16,520 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the HansBiomed Corporation stock forecast for 2026?
Our estimate puts fair value at 13,216 KRW, about 11% lower versus a price of 14,780 KRW (overvalued). Cautious scenario 9,912 KRW, optimistic scenario 16,520 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of HansBiomed Corporation (042520)?
HansBiomed Corporation reported trailing-twelve-month revenue of about 125B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of HansBiomed Corporation (042520)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HansBiomed Corporation it is 13,216 KRW per share (as of Nov 10, 2026), against a price of 14,780 KRW.
Is HansBiomed Corporation stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 042520 trades above its calculated fair value: price 14,780 KRW, fair value 13,216 KRW, a gap of about −11% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 042520?
No. The price is what the market pays today (14,780 KRW); the fair value is what the company's own numbers justify (13,216 KRW). For HansBiomed Corporation the two are 1,564 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is HansBiomed Corporation worth?
The market values HansBiomed Corporation at about 211B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 14,780 KRW; our models calculate a fair value of 13,216 KRW per share.
What do the bullish and bearish scenarios say about 042520?
Our models span a range for HansBiomed Corporation: cautious scenario 9,912 KRW, base 13,216 KRW, optimistic 16,520 KRW per share (as of Nov 10, 2026, price 14,780 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of HansBiomed Corporation (042520)?
Balance-sheet figures for HansBiomed Corporation (as of Nov 10, 2026): return on equity −29.2%, debt of 0.18 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is 042520 from its 52-week high?
HansBiomed Corporation trades at 14,780 KRW, about 73% below its 52-week high of 55,700 KRW and at the low of 14,780 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 13,216 KRW is for.
Which stocks are comparable to HansBiomed Corporation?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HansBiomed Corporation stock attractive at the current price?
The data as of Nov 10, 2026: price 14,780 KRW, calculated fair value 13,216 KRW (−11%), Quality Score 31/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. HansBiomed Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HansBiomed Corporation (042520)?
The closing price on Nov 10, 2026 was 14,780 KRW. Our estimate is 13,216 KRW, about 11% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HansBiomed Corporation right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of HansBiomed Corporation

How large is the market capitalisation of HansBiomed Corporation (042520)?
The market capitalisation of HansBiomed Corporation is 211B KRW (≈ $158M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of HansBiomed Corporation (042520)?
The price-to-sales ratio of HansBiomed Corporation is 1.95 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of HansBiomed Corporation (042520)?
Earnings per share at HansBiomed Corporation are −1,379 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of HansBiomed Corporation (042520)?
The net margin of HansBiomed Corporation is −15.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of HansBiomed Corporation (042520)?
The return on equity (ROE) of HansBiomed Corporation is −29.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HansBiomed Corporation (042520)?
On an EBIT basis the return on assets of HansBiomed Corporation is −7.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HansBiomed Corporation (042520)?
The operating margin of HansBiomed Corporation is 11.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HansBiomed Corporation (042520)?
Revenue at HansBiomed Corporation is growing +65.0% versus a year earlier (3y avg +6.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at HansBiomed Corporation (042520)?
Earnings per share at HansBiomed Corporation are growing +334% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does HansBiomed Corporation (042520) generate?
The free cash flow of HansBiomed Corporation is −1.4B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does HansBiomed Corporation (042520) carry?
The net debt of HansBiomed Corporation is 33.2B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch HansBiomed Corporation in the live analysis

One click puts HansBiomed Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.